Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 11/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089985 | 1.00 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CSRD5A1 | |
| SCHEMBL31537554 | 1.00 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CSRD5A1 | |
| SCHEMBL26814042 | 1.00 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CSRD5A1 | |
| SCHEMBL2875480 | 0.83 | SIRT1 (0.43) | PNMTADRA2AADRA2BADRA2CPRMT5 | |
| SCHEMBL12048612 | 0.83 | PNMT (0.46) | PNMTADRA2AADRA2BADRA2CSRD5A1 | |
| SCHEMBL1339915 | 0.79 | KMT2A (0.47) | PNMTADRA2AADRA2BADRA2CPRMT5 | |
| SCHEMBL30437369 | 0.79 | KMT2A (0.47) | PNMTADRA2AADRA2BADRA2CPRMT5 | |
| SCHEMBL9370418 | 0.78 | DRD2 (0.46) | — | |
| SCHEMBL19718187 | 0.77 | ALDH1A1 (0.53) | SRD5A1SRD5A2 | |
| SCHEMBL16057335 | 0.77 | PSEN1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094931-A | Synthesis method of (R) -5-halogen-2, 3-dihydro-1H-indene-2-carboxylic acid | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2026-02-19 | — | — | US | disclosed |
| US-12522582-B2 | Antiviral indolinyl compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4526289-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119546574-A | Antiviral indolinyl compounds and uses thereof | 吉利德科学公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-03-28 | — | — | US | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20050267186-A1 | 4-(Substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | CHOW KEN | 2005-12-01 | — | — | US | disclosed |
| CN-1671671-A | 4- (substituted cycloalkylmethyl) imidazole-2-thiones, 4- (substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones, and 4- (substituted cycloalkenylmethyl) imidazol-2-ones, and related compounds | ALLERGAN INC (US) | 2005-09-21 | — | — | CN | disclosed |
| US-20050075366-A1 | 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same | ALLERGAN, INC. | 2005-04-07 | — | — | US | disclosed |
| EP-1507767-A1 | 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS | Allergan, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040220402-A1 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | ALLERGAN, INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2003099795-A1 | 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0135177-B1 | BENZOCYCLOALKANE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-12-06 | — | — | EP | disclosed |
| US-4777257-A | CARDIOVASCULAR DISORDERS | DAIICHI SEIYAKU CO., LTD. (JP) | 1988-10-11 | — | — | US | disclosed |
| US-4665188-A | Certain [(1-imidazolyl)-lower-alkylene]-tetrahydronaphthalenecarboxylic acids or corresponding idan-carboxylic acids which are thromboxane A2 | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| EP-0135177-A2 | Benzocycloalkane derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | OPRK1, OPRD1, OPRM1 | PNMT 2415/4885ADRA2A 216/4885ADRA2B 238/4885 |
| US-20040220402-A1 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | ADRB2, ADRA2C, ADRB1 | PNMT 1869/4885ADRA2A 5/4885ADRA2B 4/4885 |
| US-20050267186-A1 | 4-(Substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | ADRB2, ADRA2C, ADRA2A | PNMT 2018/4885ADRA2A 3/4885ADRA2B 4/4885 |
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | MAVS, IRF3, EIF2AK2 | PNMT 509/4885ADRA2A 4565/4885ADRA2B 4660/4885 |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | PNMT 2176/4885ADRA2A 4832/4885ADRA2B 4673/4885 |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | PNMT 2176/4885ADRA2A 4832/4885ADRA2B 4673/4885 |
| US-20050075366-A1 | 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same | ADRB2, ADRA2C, ADRA2B | PNMT 1032/4885ADRA2A 4/4885ADRA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.